GoKawiilFTC accuses Martin Shkreli of violating lifetime pharma industry ban
The FTC and attorneys general from seven states have asked a federal judge to hold Martin Shkreli in contempt, alleging he repeatedly violated his 2022 lifetime ban from the pharmaceutical industry. They say he traded stock in dozens of drug companies and discussed the industry on social media livestreams despite the prohibition.
GoKawiil's interpretation of the reporting above, not reported fact.
The filing suggests regulators view Shkreli's alleged conduct as a direct test of whether court-ordered industry bans can actually be enforced against a defiant individual. If granted, the requested penalties—full divestiture, profit disgorgement, and escalating future fines—could set a precedent for how aggressively courts respond to repeated violations of such bans.
- FTC and seven states filed a contempt motion against Martin Shkreli for allegedly violating his lifetime pharma ban.
- Shkreli is accused of trading stock in multiple drug companies and discussing the industry in livestreams.
- Regulators want forced divestiture, disgorgement of trading profits, and escalating penalties for future violations.
Source: arstechnica.com, 2026-10-13
Published there as: “Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.